Aminoacyl-tRNA synthetase inhibitors as antimicrobial agents: A patent review from 2006 till present

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 12, 2012, Pages 1453-1465

  Gadakh, Bharat ^a   Van Aerschot, Arthur ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antimicrobial agents; Cyclic boronic esters; Indolmycin; Mupirocin; TRNA synthetase

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AMINO ACID TRANSFER RNA LIGASE INHIBITOR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ASPERENTIN; BORONIC ACID DERIVATIVE; BORRELIDIN; BORTEZOMIB; BUTENAFINE; CB 168; CB 432; CHLORAMPHENICOL; CICLOPIROX; DIKETONE; ERYTHROMYCIN; FLUOROQUINAZOLINE DERIVATIVE; GRISEIN; ICOFUNGIPEN; INDOLMYCIN; ITRACONAZOLE; LIGASE INHIBITOR; MICROCIN C; NAFTIFINE; PSEUDOMONIC ACID; QUINAZOLINE DERIVATIVE; SB 234764; TAVABOROLE; TERBINAFINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

AMINO ACID SEQUENCE; AMINOACYLATION; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL THERAPY; BACILLUS CEREUS; BACTERIAL MEMBRANE; BREVIBACILLUS BREVIS; CELL VIABILITY; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM PASTEURIANUM; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ESCHERICHIA COLI; FOLLOW UP; HUMAN; INFLAMMATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; NAIL INFECTION; NONHUMAN; ONYCHOMYCOSIS; PATENT; PHARMACOPHORE; PHYSICAL CHEMISTRY; POINT MUTATION; PROTEIN DOMAIN; PROTON NUCLEAR MAGNETIC RESONANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS FLUORESCENS; RACEMIC MIXTURE; RETINA ISCHEMIA; REVIEW; SACCHAROMYCES CEREVISIAE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STREPTOMYCES; STREPTOMYCES COELICOLOR; STREPTOMYCES ROCHEI; SYSTEMATIC REVIEW; TRICHOPHYTON MENTAGROPHYTES; TRYPANOSOMA; X RAY CRYSTALLOGRAPHY;

AMINO ACYL-TRNA SYNTHETASES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84869753348     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.732571     Document Type: Review

References (89)

1. Schimmel P, Tao J, Hill J. Aminoacyl tRNA synthetases as targets for new anti-infectives. FASEB J 1998;12:1599-609
2. Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007;316:1759-61
3. Ibba M, Soll D. Aminoacyl-tRNA Synthesis. Ann Rev Biochem 2000;69:617-50
4. Schimmel P, Soll D. Aminoacyl-tRNA synthetases: General features and recognition of transfer RNAs. Ann Rev Biochem 1979;48:601-48
5. Delarue M. Aminoacyl-tRNA synthetases. Curr Opin Struct Biol 1995;5:48-55
6. Vondenhoff GHM, Van Aerschot A. Aminoacyl-tRNA synthetase inhibitors as potential antibiotics. Eur J Med Chem 2011;46:5227-36
7. Cusack S. Aminoacyl-tRNA synthetases. Curr Opin Struct Biol 1997;7:881-9
8. Ataide SF, Ibba M. Small molecules: Big players in the evolution of protein synthesis. ACS Chem Biol 2006;1:285-97
9. Park SG, Schimmel P, Kim S. Aminoacyl tRNA synthetases and their connections to disease. Proc Natl Acad Sci 2008;105:11043-9
10. Ibba M, Curnow AW, Soll D. Aminoacyl-tRNA synthesis: Divergent routes to a common goal. Trends Biochem Sci 1997;22:39-42
11. Doolittle WF, Brown Jr. Tempo, mode, the progenote, and the universal root. Proc Natl Acad Sci 1994;91:6721-8
12. Brown JR, Doolittle WF. Root of the universal tree of life based on ancient aminoacyl-tRNA synthetase gene duplications. Proc Natl Acad Sci 1995;92:2441-5
13. Eriani G, Delarue M, Poch O, et al. Partition of tRNA synthetases into two classes based on mutually exclusive sets of sequence motifs. Nature 1990;347:203-6
14. Cusack S, Hartlein M, Leberman R. Sequence, structural and evolutionary relationships between class 2 aminoacyl-tRNA synthetases. Nucleic Acids Res 1991;19:3489-98
15. Rao ST, Rossmann MG. Comparison of super-secondary structures in proteins. J Mol Biol 1973;76:241-56
16. Ochsner UA, Sun X, Jarvis T, et al. Aminoacyl-tRNA synthetases: Essential and still promising targets for new anti-infective agents. Expert Opin Investig Drugs 2007;16:573-93
17. Hurdle JG, O'Neill AJ, Chopra I. Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. Antimicrob Agents Chemother 2005;49:4821-33
18. Kim S, Lee SW, Choi EC, Choi SY. Aminoacyl-tRNA synthetases and their inhibitors as a novel family of antibiotics. Appl Microbiol Biotechnol 2003;61:278-88
19. Tao J, Wendler P, Connelly G, et al. Drug target validation: Lethal infection blocked by inducible peptide. Proc Natl Acad Sci 2000;97:783-6
20. Raczniak G, Ibba M, Soll D. Genomics-based identification of targets in pathogenic bacteria for potential therapeutic and diagnostic use. Toxicology 2001;160:181-9
21. Bunk DM, Dalluge JJ, Welch MJ. Heterogeneity in human cardiac troponin I standards. Anal Biochem 2000;284:191-200
22. Ibba M, Francklyn C, Cusack S. The aminoacyl-tRNA synthetases. Landes Bioscience/Eurekah.com; Georgetown, Texas, USA. 2005
23. Pohlmann J, Brotz-Oesterhelt H. New aminoacyl-tRNA synthetase inhibitors as antibacterial agents. Curr Drug Targets Infect Disord 2004;4:261-72
24. Hughes J, Mellows G, Soughton S. How does pseudomonas fluorescens, the producing organism of the antibiotic pseudomonic acid A, avoid suicide? FEBS Lett 1980;122:322-4
25. Yanagisawa T, Lee JT, Wu HC, Kawakami M. Relationship of protein structure of isoleucyl-tRNA synthetase with pseudomonic acid resistance of Escherichia coli. A proposed mode of action of pseudomonic acid as an inhibitor of isoleucyl-tRNA synthetase. J Biol Chem 1994;269:24304-9
26. Silvian LF, Wang J, Steitz TA. Insights into editing from an Ile-tRNA synthetase structure with tRNAIle and mupirocin. Science 1999;285:1074-7
27. Pappa KA. The clinical development of mupirocin. J Am Acad Dermatol 1990;22:873-9
28. Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clinical Infect Dis 2009;49:935-41
29. Werner RG, Thorpe LF, Reuter W, Nierhaus KH. Indolmycin inhibits prokaryotic tryptophanyl-tRNA ligase. Eur J Biochem 1976;68:1-3
30. Kitabatake M, Ali K, Demain A, et al. Indolmycin resistance of Streptomyces coelicolor A3(2) by Induced expression of one of Its two tryptophanyl-tRNA synthetases. J Biol Chem 2002;277:23882-7
31. Hurdle JG, O'Neill AJ, Chopra I. Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections. J Antimicrob Chemother 2004;54:549-52
32. Kanamaru T, Nakano Y, Toyoda Y, et al. In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection. Antimicrob Agents Chemother 2001;45:2455-9
33. Vino S, Lokesh KR. Borrelidin: A promising anticancer agent from Streptomyces species. Adv Biotech 2008;6:22-6
34. Olano C, Moss SJ, Brana AF, et al. Biosynthesis of the angiogenesis inhibitor borrelidin by Streptomyces parvulus Tu4055: Insights into nitrile formation. Mol Microbiol 2004;52:1745-56
35. Kuo MS, Yurek DA, Kloosterman DA. Assignment of 1H and 13C NMR signals and the alkene geometry at C-7 in borrelidin. J Antibiot (Tokyo) 1989;42:1006-7
36. Ruan BF, Bovee ML, Sacher M, et al. A unique hydrophobic cluster near the active site contributes to differences in borrelidin inhibition among threonyl-tRNA synthetases. J Biol Chem 2005;280:571-7
37. Paetz W, Nass G. Biochemical and immunological characterization of threonyl-tRNA synthetase of two borrelidin-resistant mutants of Escherichia coli. Eur J Biochem 1973;35:331-7
38. Nass G, Poralla K, Zahner H. Effect of the antibiotic borrelidin on the regulation of threonine biosynthetic enzymes in E. coli. Biochem Biophys Res Commun 1969;34:84-91
39. Gerken SC, Arfin SM. Chinese hamster ovary cells resistant to borrelidin overproduce threonyl-tRNA synthetase. J Biol Chem 1984;259:9202-6
40. Kazakov T, Vondenhoff GH, Datsenko KA, et al. Escherichia coli peptidase A, B, or N can process translation inhibitor microcin C. J Bacteriol 2008;190:2607-10
41. Tikhonov A, Kazakov T, Semenova E, et al. The mechanism of microcin C resistance provided by the MccF peptidase. J Biol Chem 2010;285:37944-52
42. Novikova M, Metlitskaya A, Datsenko K, et al. The Escherichia coli Yej transporter is required for the uptake of translation inhibitor microcin C. J Bacteriol 2007;189:8361-5
43. Van de Vijver P, Vondenhoff GHM, Kazakov TS, et al. Synthetic microcin C analogs targeting different aminoacyl-tRNA synthetases. J Bacteriol 2009;191:6273-80
44. Zeng Y, Roy H, Patil PB, et al. Characterization of two seryl-tRNA synthetases in albomycin-producing streptomyces sp. Strain ATCC 700974. Antimicrob Agents Chemother 2009;53:4619-27
45. Gause GF. Recent studies on albomycin, a new antibiotic. Br Med J 1955;2:1177-9
46. Pramanik A, Stroeher UH, Krejci J, et al. Albomycin is an effective antibiotic, as exemplified with Yersinia enterocolitica and Streptococcus pneumoniae. Int J Med Microbiol 2007;297:459-69
47. Hoepfner D, McNamara CW, Lim CS, et al. Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe 2012;11:654-63
48. Anke H. Metabolic products of microorganisms. 184. On the mode of action of cladosporin. J Antibiot (Tokyo) 1979;32:952-8
49. Forrest A, Osborne NF, Pengelly D; inventors. Mupirocinsulfamates with antibacterial activity. WO005126A1; 1997
50. Forrest AK, Jarvest RL, Mensah LM, et al. Aminoalkyl adenylate and aminoacyl sulfamate intermediate analogues differing greatly in affinity for their cognate Staphylococcus aureus aminoacyl tRNA synthetases. Bioorg Med Chem Lett 2000;10:1871-4
51. Hill JM, Yu G, Zydowsky TM, Rebek J; inventors; Cubist Pharmaceuticals, Inc., assignee. Aminoacyl adenylate mimics as novel anitmicrobial and antiparasitic agents. US5726195; 1998
52. Farrera-Sinfreu J, Espanol Y, Geslain R, et al. Solid-phase combinatorial synthesis of a lysyl-tRNA synthetase (LysRS) inhibitory library. J Comb Chem 2008;10:391-400
53. Bennett I, Broom NJP, Cassels R, et al. Synthesis and antibacterial properties of beta-diketone acrylate bioisosteres of pseudomonic acid A. Bioorg Med Chem Lett 1999;9:1847-52
54. Brown MJB, Mensah LM, Doyle ML, et al. Rational design of femtomolar inhibitors of isoleucyl tRNA synthetase from a binding model for pseudomonic acid-A. Biochemistry 2000;39:6003-11
55. Konishi M, Nishio M, Saitoh K, et al. Cispentacin, a new antifungal antibiotic. I. Production, isolation, physico-chemical properties and structure. J Antibiot 1989;42:1749-55
56. Mittendorf J, Kunisch F, Matzke M, et al. Novel antifungal beta-amino acids: Synthesis and activity against Candida albicans. Bioorg Med Chem Lett 2003;13:433-6
57. Petraitiene R, Petraitis V, Kelaher AM, et al. Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2005;49:2084-92
58. Hasenoehrl A, Galic T, Ergovic G, et al. In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans. Antimicrob Agents Chemother 2006;50:3011-18
59. Critchley IA, Green LS, Young CL, et al. Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections. J Antimicrob Chemother 2009;63:954-63
60. Shibata S, Gillespie JR, Kelley AM, et al. Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice. Antimicrob Agents Chemother 2011;55:1982-9
61. Shibata S, Gillespie JR, Ranade RM, et al. Urea-Based Inhibitors of Trypanosoma brucei Methionyl-tRNA Synthetase: Selectivity and in Vivo Characterization. J Med Chem 2012;55:6342-51
62. Balg C, De Mieri M, Huot JL, et al. Inhibition of Helicobacter pylori aminoacyl-tRNA amidotransferase by chloramphenicol analogs. Bioorg Med Chem 2010;18:7868-72
63. Das B, Arora JS, Ahmed S, et al. inventors; Ranbaxy Laboratories Limited, assignee. Antimicrobial agents. WO117762A2; 2006
64. Das B, Arora JS, Ahmed S, et al. inventors; Ranbaxy Laboratories Limited, assignee. Antimicrobial agents. US0215764A1; 2009
65. Das B, Upadhyay DJ, Purnapatre K, inventors; Ranbaxy Laboratories Limited, assignee. Heterocyclic sulfonamides as inhibitors of transfer RNA synthetase for use as antibacterial agents. WO014109A1; 2012
66. Ahmed S, Das B, Upadhyay DJ; inventors; Ranbaxy Laboratories Limited, assignee. Isoindole derivatives as antimicrobial agents. WO029076A1; 2007
67. Baker SJ, Akama T, Carolyn BK, et al. inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. US7582621B2; 2009
68. Baker SJ, Akama T, Carolyn BK, et al. inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. US8039451B2; 2011
69. Baker SJ, Akama T, Carolyn BK, et al. inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. WO0234981A1; 2006
70. Baker SJ, Akama T, Alley MRK, et al. inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. US8115026B2; 2012
71. Baker SJ, Tsutomu A, Carolyn BK, et al. inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. US0319361A1; 2011
72. Baker SJ, Akama T, Alley MRK, et al. inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. WO0155699A1; 2007
73. Baker SJ, Akama T, Alley MRK, et al. inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. WO078340A2; 2007
74. Baker SJ, Hernandez VS, Sharma R, et al. inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. US7816344B2; 2010
75. Baker SJ, Hernandez VS, Sharma R, et al. inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. WO157726A1; 2008
76. Zhou H, Ding D, Zhou Y, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules as antiprotozoal agents. WO022337A1; 2011
77. Hernandez V, Ding C, Plattner J, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. WO037731A1; 2011
78. Hernandez VS, Ding C, Plattner J, inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. US0124597; 2011
79. Hernandez VS, Li X, Zhang S, et al. inventors; Anacor Pharmaceuticals, Inc., assignee. Boron containing small molecules. WO060199A1; 2011
80. Guiles J, Xicheng S, Janjic N, Strong S; inventors; Replidyne, Inc., assignee. Substituted phenylether-thienopyridone compounds with antibacterial activity. WO039641A2; 2008
81. Guiles J, Sun X, Janjic N, Strong S; inventors; Replidyne, Inc., assignee. Substituted phenylether-thienopyridone compounds with antibacterial activity. US0227808A1; 2008
82. Guiles J, Sun X, Janjic N, Strong S; inventors; Crestone, Inc., assignee. Substituted thienopyridone compounds with antibacterial activity. US7994192B2; 2011
83. Guiles J, Sun X, Janjic N, Strong S; inventors; Replidyne, Inc., assignee. Substituted thienopyridone compounds with antibacterial activity. WO039639A2; 2008
84. Guiles J, Sun X, Janjic N, Strong S; inventors; Replidyne, Inc., assignee. Substituted-thienopyridone compounds with antibacterial activity. WO0146609A1; 2008
85. Guiles J, Sun X, Janjic N, inventors; Replidyne, Inc., assignee. Enantiomeric compounds with antibacterial activity. WO039640A2; 2008
86. Guiles J, Sun X, Janjic N, inventors; Crestone, Inc., assignee. Enantiomeric compounds with antibacterial activity. US7973050B2; 2011
87. Guiles J, Sun X, Janjic N, Strong S; inventors; Replidyne, Inc., assignee. Methods and compositions for treatment of Clostridium based infection. WO039642A2; 2008
88. Mayer FK; inventor; Novartis AG, assignee. Pharmaceutical compositions for the treatment of fungal infections. WO025543A1; 2008
89. Sello JK, Vecchione JJ; inventors; Brown University, assignee. Combination of an aminoacyl-tRNA synthetase inhibitor with a further antibacterial agents for attenuating multiple drug resistance. WO054738A1; 2012